Antonio S.
- Country
- France
- Department
- Hépato-Gastro-Entérologie
Research Overview
- Neoadjuvant and Adjuvant Durvalumab and Tremelimumab in Hepatocellular Carcinoma Patients Undergoing Curative Percutaneous Ablation
- Neoadjuvant and Adjuvant Lenvatinib in BCLC A Hepatocellular Carcinoma with Percutaneous Ablation: A Multicenter Pilot Study
- Phase II Evaluation of Tislelizumab Monotherapy in Hepatocellular Carcinoma Patients with Child-Pugh B and ALBI Grade 1/2 Liver Function
Data & Insights
Has run more than one trial at 14 of 27 partner sites.
Specializations
Liver Cancer Therapeutics
This investigator specializes in innovative treatments for hepatocellular carcinoma (HCC), with particular emphasis on therapeutic approaches for patients with varying liver function status.
- Percutaneous ablation procedures
- Immunotherapy applications
- Targeted therapeutic interventions
The investigator focuses on curative treatment strategies for BCLC A hepatocellular carcinoma patients.
Immunological Approaches
Expertise in developing immunotherapy protocols for liver cancer patients, including those with moderately altered liver functions.
- Anti-PD1 therapy evaluation
- Combined immunotherapy approaches
- Child-Pugh B population treatment
Special interest in neoadjuvant and adjuvant immunotherapy applications for hepatic malignancies.
Advanced Treatment Modalities
Development of combination therapies incorporating targeted molecular agents and interventional procedures.
- Multi-modal treatment strategies
- Novel therapeutic combinations
- Local recurrence prevention
Focus on treatment optimization for patients with varying tumor characteristics and liver function parameters.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.